Equities Analysts Set Expectations for LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for Lexeo Therapeutics in a note issued to investors on Monday, November 17th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($2.00) per share for the year, up from their previous forecast of ($2.21). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q4 2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.33) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.34) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.15.

Several other equities analysts also recently issued reports on LXEO. Guggenheim initiated coverage on shares of Lexeo Therapeutics in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 price objective on the stock. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Chardan Capital restated a “buy” rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday, November 5th. Leerink Partners upped their target price on Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Finally, Oppenheimer started coverage on Lexeo Therapeutics in a research report on Thursday, July 31st. They set an “outperform” rating and a $20.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.57.

Lexeo Therapeutics Price Performance

Lexeo Therapeutics stock opened at $9.18 on Wednesday. The stock has a market capitalization of $670.05 million, a P/E ratio of -3.40 and a beta of 1.75. Lexeo Therapeutics has a 12-month low of $1.45 and a 12-month high of $10.38. The firm’s 50-day moving average is $7.81 and its two-hundred day moving average is $5.39.

Hedge Funds Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LXEO. CWM LLC increased its position in Lexeo Therapeutics by 150.3% during the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock worth $42,000 after purchasing an additional 6,216 shares in the last quarter. Ethic Inc. purchased a new stake in Lexeo Therapeutics during the second quarter worth approximately $44,000. Cerity Partners LLC acquired a new stake in shares of Lexeo Therapeutics in the second quarter worth $50,000. Intech Investment Management LLC increased its position in shares of Lexeo Therapeutics by 20.7% in the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock worth $55,000 after acquiring an additional 2,342 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at $60,000. 60.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, insider Eric Adler sold 3,382 shares of the business’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $30,235.08. Following the completion of the sale, the insider owned 73,261 shares of the company’s stock, valued at approximately $654,953.34. The trade was a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Richard Nolan Townsend sold 13,133 shares of the company’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $117,409.02. Following the sale, the chief executive officer owned 242,118 shares of the company’s stock, valued at $2,164,534.92. This represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 22,518 shares of company stock worth $201,311 in the last ninety days. Insiders own 5.30% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.